Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
SOTORASIB, Dexamethasone 2mg Tablets, DOCETAXEL
Amgen
Previously treated locally advanced and unresectable or metastatic non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation
1 trial -
SOTORASIB, Stivarga 40 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, Vectibix 20 mg/ml concentrate for solution for infusion, Stivarga 40 mg film-coated tablets, Vectibix 20 mg/ml concentrate for solution for infusion, Lonsurf 15 mg/6.14 mg film-coated tablets
Amgen
Colorectal Cancer (CRC)
1 trial -
SOTYKTU 6 mg film-coated tablets, Matching Placebo for Deucravacitinib, SOTYKTU 6 mg film-coated tablets, SOTYKTU 6 mg film-coated tablets, ZASOCITINIB, SOTYKTU 6 mg film-coated tablets, Matching Placebo for TAK-279
Takeda
Moderate to Severe Plaque Psoriasis
1 trial -
SPD476, MMXβ’ mesalazine, 1.2g extended release tablet
Takeda
Diverticulitis
1 trial -
SR-A + Epratuzumab
United Therapeutics Europe Ltd
Acute Lymphoblastic Leukemia (ALL)
1 trial -
STAGE-12
BRIGHT MINDS BIOSCIENCES INC.
Drug Abuse
1 trial -
STELARA 90 mg solution for injection in pre-filled syringe, Guselkumab, STELARA 45 mg solution for injection, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL
Janssen-Cilag International N.V.
Juvenile psoriatic arthritis
1 trial -
STELARA 90 mg solution for injection in pre-filled syringe, Solution for injection in pre-filled syringe without Ustekinumab 45, Solution for injection in pre-filled syringe without Ustekinumab 90, STELARA 45 mg solution for injection, JNJ-77242113-AAC Placebo tablet, JNJ-77242113
Janssen-Cilag International N.V.
Active Psoriatic Arthritis
1 trial -
SYLVANT 400 mg powder for concentrate for solution for infusion, ABIRATERONE ACETATE, AMG 509, ABIRATERONE ACETATE, ENZALUTAMIDE, AMG 509, AMG 509, CABAZITAXEL
Amgen
Metastatic castration-resistant prostate cancer (mCRPC)
1 trial -
SYR-472
Takeda
Type 2 Diabetes Mellitus
1 trial -
SYR-472
Takeda
Diabetes Mellitus
5 trials -
Sabin Strain Inactivated Poliovirus Vaccine
Sinovac Research and Development Co.,
Poliomyelitis
1 trial -
Sacituzumab Govitecan-hziy
Gilead Sciences Ireland UC
Triple Negative Breast Cancer
1 trial -
Sacituzumab tirumotecan
Merck KGaA, Darmstadt, Germany
Non-small Cell Lung Cancer (NSCLC)
2 trials -
Sacituzumab tirumotecan
Merck KGaA, Darmstadt, Germany
Breast Neoplasms
1 trial -
Sacituzumab tirumotecan
Merck KGaA, Darmstadt, Germany
Non Small Cell Lung Cancer
1 trial -
Safinamide 100 mg PLACEBO: Safinamide 100 mg PLACEBO film-coated tablets have the same composition as the relevant Investigational Medicinal Products except for the presence of Active Substance that is missing in the placebo formulations. The missing amount of active substance Safinamide methanesulfonate is replaced in the PLACEBO formulation with the same amount of Microcrystalline cellulose, one of the excipients already present in the authorised formulation, Xadago 100 mg film-coated tablets, Xadago 50 m
Verona Pharma Ireland Limited
PARKINSONβS DISEASE WITH MOTOR FLUCTUATIONS
1 trial -
Saline Solution Basi 9 mg/ml solution for infusion, Felzartamab
Biogen
Kidney Transplant Recipients with Late Antibody-Mediated Rejection
1 trial -
Saphnelo 300 mg concentrate for solution for infusion, Anifrolumab Placebo
AstraZeneca AB
Active Proliferative Lupus Nephritis
1 trial -
Sar444671 placebo - matched placebo for test, Rilzabrutinib
Sanofi-aventis Healthcare Pty Ltd
Autoimmune haemolytic anaemia
1 trial -
Sar444671 placebo - matched placebo for test, Rilzabrutinib
Sanofi-aventis Healthcare Pty Ltd
Blood and lymphatic diseases
1 trial -
Sarilumab
Regeneron UK Limited
COVID-19
1 trial -
Sarilumab
Sanofi Pasteur
Rheumatoid Arthritis
1 trial -
Sarilumab
Regeneron UK Limited
RA
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources